

CONNECTICUT Diabetes Data & Forecasts



State Total Population Forecasts	2015	2020	2025	2030
Entire Population	3,635,400	3,675,700	3,691,000	3,688,600
Prediabetes	1,006,100	1,050,800	1,086,800	1,087,500
Diagnosed diabetes	252,300	302,100	341,100	368,100
Undiagnosed diabetes	105,700	120,200	128,800	131,600
Total with diabetes (diagnosed and undiagnosed)	358,000	422,300	469,900	499,700
Complications:				
Visual impairment	41,400	48,100	52,700	55,200
Renal failure	600	690	760	790
Leg amputations	520	570	600	590
Annual deaths attributable to diabetes	2,720	3,110	3,330	3,400
Total annual cost (2015 dollars)	\$4.5 B	\$5.3 B	\$5.9 B	\$6.3 B
Annual medical costs	\$3.4 B	\$3.9 B	\$4.3 B	\$4.6 B
Annual nonmedical costs	\$1.1 B	\$1.4 B	\$1.6 B	\$1.7 B

State Senior Population Forecasts	2015	2020	2025	2030
Population 65 and older	577,100	642,500	723,300	794,400
Prediabetes	294,300	327,700	368,900	405,100
Diagnosed diabetes	109,100	121,400	136,700	150,200
Undiagnosed diabetes	40,400	45,000	50,600	55,600
Total with diabetes (diagnosed and undiagnosed)	149,500	166,400	187,300	205,800
Complications:				
Visual impairment	20,400	22,100	24,300	26,000
Renal failure	340	360	390	420
Leg amputations	250	260	270	270
Annual deaths attributable to diabetes	1,870	2,080	2,160	2,140
Total annual cost (2015 dollars)	\$1.9 B	\$2.1 B	\$2.4 B	\$2.6 B
Annual medical costs	\$1.8 B	\$2.0 B	\$2.2 B	\$2.4 B
Annual nonmedical costs	\$0.1 B	\$0.1 B	\$0.2 B	\$0.2 B

These forecasts are based on the latest available national diabetes data, including U.S Census Bureau population projections, the CDC National Diabetes Statistics Report, 2014, CDC diabetes morbidity trend reports, CDC's latest diabetes prevalence projections to 2050 and Dall, et al. "The Economic Burden of Elevated Blood Glucose Levels in 2012: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes," *Diabetes Care* 2014;37:3172-3179. These forecasts assume a steady, but conservative, reduction in the number of people with complications due to better awareness of the risks of diabetes, earlier screening and intervention, and more effective therapies.

For details and references on the Institute for Alternative Futures Diabetes 2030 Forecasting Model Methodology, visit www.altfutures.org/diabetes2030.

Research funded by Novo Nordisk Inc.